Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.47 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.47 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.47 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.47 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.47 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29953294 | 1.00 | CYP1A2 (0.47) | CYP1A2CYP2D6CYP2C9CYP2C19SLC6A1 | |
| SCHEMBL29956504 | 1.00 | CYP1A2 (0.47) | CYP1A2CYP2D6CYP2C9CYP2C19SLC6A1 | |
| Hydrochloric Acid SCHEMBL15572481 | 0.98 | CYP1A2 (0.46) | CYP1A2CYP2D6CYP2C9CYP2C19SLC6A1 | |
| SCHEMBL10615013 | 0.96 | CYP1A2 (0.45) | CYP1A2CYP2D6CYP2C9CYP2C19SLC6A1 | |
| SCHEMBL28840987 | 0.86 | CYP1A2 (0.41) | CYP1A2CYP2D6CYP2C9CYP2C19SLC6A1 | |
| SCHEMBL16771733 | 0.82 | SLC6A2 (0.39) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL2881934 | 0.82 | SLC6A2 (0.36) | CYP1A2CYP2D6CYP2C9CYP2C19SLC6A1 | |
| SCHEMBL6519388 | 0.82 | ADRA2C (0.39) | CYP2D6SLC6A2SLC6A3SLC6A4HTR2A | |
| SCHEMBL21555626 | 0.82 | GABRA5 (0.46) | CYP1A2CYP2D6CYP2C9CYP2C19SLC6A1 | |
| SCHEMBL2442395 | 0.82 | ADRA2C (0.39) | CYP2D6SLC6A2SLC6A3SLC6A4HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118028412-A | Extraction processing technology of rice protein | 安徽稼仙金佳粮集团股份有限公司 | 2024-05-14 | — | — | CN | claimed |
| CN-112480141-A | Pyranocoumarin derivative and preparation method and application thereof | 吉林大学珠海学院 | 2021-03-12 | — | — | CN | claimed |
| US-9833768-B2 | Affinity reagents for protein purification | IMPOSSIBLE FOODS INC. (US) | 2017-12-05 | — | — | US | claimed |
| US-20170320041-A1 | AFFINITY REAGENTS FOR PROTEIN PURIFICATION | IMPOSSIBLE FOODS INC. | 2017-11-09 | — | — | US | claimed |
| EP-2277884-B1 | ANTHRACYCLINE ANTIBIOTIC DERIVATIVES WITH HIGH ACTIVITY, PREPARATION METHODS AND USES THEREOF | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO LTD (CN) | 2017-08-23 | — | — | EP | claimed |
| US-9737875-B2 | Affinity reagents for protein purification | IMPOSSIBLE FOODS INC. (US) | 2017-08-22 | — | — | US | claimed |
| US-9115165-B2 | Tetracyclic anthraquinone antibiotic derivatives with high activity, process for preparing the same and use thereof | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2015-08-25 | — | — | US | claimed |
| US-20140309192-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC, | 2014-10-16 | — | — | US | claimed |
| CN-104105691-A | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC | 2014-10-15 | — | — | CN | claimed |
| EP-2776407-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2014-09-17 | — | — | EP | claimed |
| WO-2013070657-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2013-05-16 | — | — | WO | claimed |
| CN-102939292-A | Spirocyclic compounds and their use as therapeutic agents and diagnostic probes | UNIV BASEL | 2013-02-20 | — | — | CN | claimed |
| US-20130040934-A1 | SPIROCYCLIC COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2013-02-14 | — | — | US | claimed |
| EP-2547684-A1 | SPIROCYCLIC COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | University of Basel (CH) | 2013-01-23 | — | — | EP | claimed |
| WO-2011114275-A1 | SPIROCYCLIC COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2011-09-22 | — | — | WO | claimed |
| US-20110224161-A1 | TETRACYCLIC ANTHRAQUINONE ANTIBIOTIC DERIVATIVES WITH HIGH ACTIVITY, PROCESS FOR PREPARING THE SAME AND USE THEREOF | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2011-09-15 | — | — | US | claimed |
| EP-2277884-A1 | ANTHRACYCLINE ANTIBIOTIC DERIVATIVES WITH HIGH ACTIVITY, PREPARATION METHODS AND USES THEREOF | Tianjin Hemay Bio-Tech Co., Ltd. (CN) | 2011-01-26 | — | — | EP | claimed |
| US-20260076982-A1 | Prodrugs of Cannbidiol [CBD]-Type Phytocannabinoids and a Process for Preparation Thereof | COUNCIL SCIENT IND RES (IN) | 2026-03-19 | — | — | US | disclosed |
| US-20040176405-A1 | Methods and compounds for inhibitting MRP1 | KROIN JULIAN (US) | 2004-09-09 | — | — | US | disclosed |
| EP-0452392-A1 | HETEROCYCLIC CHELATING AGENTS. | NYCOMED AS (NO) | 1991-10-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224161-A1 | TETRACYCLIC ANTHRAQUINONE ANTIBIOTIC DERIVATIVES WITH HIGH ACTIVITY, PROCESS FOR PREPARING THE SAME AND USE THEREOF | DHPS, TBCA, ANTXR2 | CYP1A2 324/4885CYP2D6 77/4885CYP2C9 693/4885 |
| US-20260076982-A1 | Prodrugs of Cannbidiol [CBD]-Type Phytocannabinoids and a Process for Preparation Thereof | CNR1, CNR2, CBR1 | CYP1A2 67/4885CYP2D6 92/4885CYP2C9 49/4885 |
| US-20040176405-A1 | Methods and compounds for inhibitting MRP1 | ABCC1, ABCB11, ABCB1 | CYP1A2 478/4885CYP2D6 278/4885CYP2C9 610/4885 |
| US-20170320041-A1 | AFFINITY REAGENTS FOR PROTEIN PURIFICATION | RAB5IF, MRPL21, RPS27A | CYP1A2 4878/4885CYP2D6 4848/4885CYP2C9 4831/4885 |
| US-20140309192-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | MRGPRX1, MRGPRX2, AGTR1 | CYP1A2 3723/4885CYP2D6 3408/4885CYP2C9 4631/4885 |
| US-20130040934-A1 | SPIROCYCLIC COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | CDK4, GRK4, RPS6KA4 | CYP1A2 3338/4885CYP2D6 1542/4885CYP2C9 3732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.